A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson's disease finds that it is reasonably safe and well tolerated. Researchers also report finding an increase in dopamine, the chemical ...
Dec 16, 2019
0
2
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric ...
Dec 9, 2019
0
5
Why do some cancers come back? Sometimes, a treatment can effectively eliminate cancer cells to undetectable levels, but, if the treatment stops, cancer may return. This is the case of chronic myeloid leukemia treated with ...
Nov 7, 2019
0
34
Neuroscientists at Georgetown University Medical Center say they have developed and tested an agent that reduces the buildup of toxic proteins in animal models of both Parkinson's and Alzheimer's diseases, and improves cognitive ...
Oct 23, 2019
0
473
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...
Oct 16, 2019
0
1021
DDR1 is a receptor tyrosine kinase (RTK)—a cell surface receptor—that regulates multiple functions including the maintenance of the normal structure of tissues, but which also contributes to pathological conditions including ...
Aug 9, 2019
0
3
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the ...
Jun 11, 2019
0
13
An important class of drug used to treat cancer patients could be used to treat brain aneurysms, according to new research published this week.
May 17, 2019
0
154
(HealthDay)—The selective Bruton's tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, ...
May 14, 2019
0
2
There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...
Apr 30, 2019
0
1
